Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 3,785 matching trials from the live ClinicalTrials.gov search.
Conditions
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
Interventions
RSP-1502, Tobramycin inhalation solution
Drug
Lead sponsor
Respirion Pharmaceuticals Pty Ltd
Industry
Eligibility
12 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Conditions
Von Willebrand Diseases
Interventions
VGA039, Placebo
Drug · Other
Lead sponsor
Vega Therapeutics, Inc
Industry
Eligibility
12 Years to 60 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more
Conditions
Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma
Interventions
Pralatrexate Injection, Bexarotene Capsules, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Stanford, California • New York, New York • Pittsburgh, Pennsylvania + 1 more
Conditions
Healthy Volunteers
Interventions
ITI-333, Placebo
Drug · Other
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Miami, Florida
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Phase I and Phase II: LAE001/prednisone + afuresertib
Drug
Lead sponsor
Laekna Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Tucson, Arizona • Encinitas, California • Norwich, Connecticut + 9 more
Conditions
Dyslipidemia
Interventions
AZD0780, Placebo, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Conditions
Malignant Melanoma
Interventions
Cobimetinib, vemurafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 6 more
Active, not recruiting Phase 2 Interventional Results available

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

NCT04126070
Conditions
Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma
Interventions
Androgen Deprivation Therapy, Nivolumab, Docetaxel
Drug
Lead sponsor
Xiao X. Wei, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
La Jolla, California • Tampa, Florida • Baltimore, Maryland + 2 more
Conditions
Systemic Lupos Erythematosus, SLE
Interventions
BIIB068, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Evansville, Indiana
Conditions
Xerostomia, Head and Neck Squamous Cell Carcinoma
Interventions
Dexamethasone 4mg/mL, Dexamethasone 10mg/mL
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sacramento, California
Conditions
Gastroparesis, Lung Transplant; Complications
Interventions
High Resolution Electrogastography
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Houston, Texas • Charlottesville, Virginia
Conditions
Postoperative Pain Management
Interventions
EXPAREL and Bupivacaine, Standard of Care
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
New Haven, Connecticut • Boca Raton, Florida • Miami, Florida + 9 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A MAD Study of TT301/MW189 in Healthy Volunteers

NCT02942771
Conditions
Healthy Adult Volunteers
Interventions
0.075mg/kg TT301/MW189, 0.15mg/kg TT301MW189, 0.25mg/kg TT301/MW189, 0.30mg/kg TT301/MW189, Placebo
Drug
Lead sponsor
Linda Van Eldik
Other
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, sargramostim, therapeutic autologous lymphocytes, O6-benzylguanine, carmustine, temozolomide, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Terminated Not applicable Interventional Accepts healthy volunteers

Ginger.io Behavioral Health Study

NCT02491307
Conditions
Anxiety, Depression, Bipolar I Disorder, Bipolar II Disorder
Interventions
Ginger.io Smartphone Application
Other
Lead sponsor
Community Health Center, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
4
States / cities
Meriden, Connecticut • Middletown, Connecticut • New Britain, Connecticut + 1 more
Conditions
Colorectal Cancer
Interventions
Cemiplimab, Fianlimab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma
Interventions
Cemiplimab, Computed Tomography, Biospecimen Collection, Quality-of-Life Assessment, Magnetic Resonance Imaging, Biopsy, Fianlimab
Biological · Procedure · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
3
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Nashville, Tennessee
Conditions
Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions
PF-08046876, Pembrolizumab, Cisplatin, Carboplatin
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
21
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 11 more
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Azacitidine Injection, sodium phenylbutyrate
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Neurodevelopmental Outcomes in ZIKV-Exposed Children

NCT04398901
Conditions
Zika Virus, Congenital Zika Syndrome, Congenital Infection, Child Development
Interventions
Neurodevelopmental assessments
Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
3 Years to 7 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Vaccine Adverse Reaction, Post Acute Covid-19 Vaccination Syndrome
Interventions
Combined metabolic modulator, Rice Protein Powder with Vitamin C
Combination Product · Dietary Supplement
Lead sponsor
Independent Medical Alliance
Other
Eligibility
16 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Completed No phase listed Observational Accepts healthy volunteers

Audio Data Collection for Identification and Classification of Coughing

NCT04326309
Conditions
COVID-19, Coronavirus Infections, Hay Fever, Asthma, Chronic Obstructive Pulmonary Disease, Influenza, Common Cold, Respiratory Tract Infections, Healthy
Interventions
Not listed
Lead sponsor
HealthMode Inc.
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Pancreatic Cancer
Interventions
N-803, Aldoxorubicin HCl, PD-L1 t-haNK, Nab-paclitaxel, Gemcitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, SBRT, Irinotecan liposome
Biological · Drug · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
El Segundo, California • Newport Beach, California • East Brunswick, New Jersey + 1 more
Conditions
Chronic Kidney Disease
Interventions
KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey